Patrick Yeramian
Corporate Officer/Principal presso Dlx Therapeutics L L C
Patrimonio netto: 583 918 $ in data 31/03/2024
Profilo
Patrick D.
Yeramian is currently the General Manager at Dlx Therapeutics L L C.
Previously, he worked as a Medical Director at Pfizer Inc., Marker Therapeutics, Inc., Vaccine & Gene Therapy Institute of Florida Corp., Kantum Pharma, Inc., and Tapimmune, Inc. He also served as the Director-Clinical Research at G.D.
Searle LLC and as the Chief Medical Officer at Viragen, Inc. and BioVie, Inc. Additionally, he is currently the Chief Medical Officer & Global Head-Clinical R&D at Amylyx Pharmaceuticals, Inc. Dr. Yeramian holds a graduate degree from Université de Paris XI Paris Sud, a doctorate from Universite Paris Est.
Creteil Val De Marne, and an MBA from Rutgers Business School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 09/01/2024 | 205 605 ( 0.30% ) | 583 918 $ | 31/03/2024 |
Posizioni attive di Patrick Yeramian
| Società | Posizione | Inizio |
|---|---|---|
| Dlx Therapeutics L L C | Corporate Officer/Principal | 01/01/2018 |
Precedenti posizioni note di Patrick Yeramian
| Società | Posizione | Fine |
|---|---|---|
| AMYLYX PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 28/11/2023 |
| BIOVIE INC. | Chief Tech/Sci/R&D Officer | 01/11/2021 |
Kantum Pharma, Inc.
 Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Chief Tech/Sci/R&D Officer | 01/03/2019 |
| MARKER THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2017 |
| Tapimmune, Inc. | Chief Tech/Sci/R&D Officer | 01/01/2017 |
Formazione di Patrick Yeramian
| Universite Paris Est Creteil Val De Marne | Doctorate Degree |
| Rutgers Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| PFIZER, INC. | Health Technology |
| MARKER THERAPEUTICS, INC. | Health Technology |
| BIOVIE INC. | Health Technology |
| AMYLYX PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 7 |
|---|---|
Viragen, Inc.
 Viragen, Inc. BiotechnologyHealth Technology Viragen, Inc. is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. The firm is located in Plantation, FL. | Health Technology |
| Université de Paris XI Paris Sud | Consumer Services |
| G.D. Searle LLC | |
Vaccine & Gene Therapy Institute of Florida Corp.
 Vaccine & Gene Therapy Institute of Florida Corp. Miscellaneous Commercial ServicesCommercial Services Vaccine & Gene Therapy Institute of Florida Corp. provides research services. The non-profit company is based in Port Saint Lucie, FL. | Commercial Services |
Kantum Pharma, Inc.
Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Commercial Services |
| Dlx Therapeutics L L C | |
| Tapimmune, Inc. |
- Borsa valori
- Insiders
- Patrick Yeramian
